As per the agreement, KellBenx is expected to get worldwide rights for the commercialization of the antibodies which allow the extraction of clinically relevant information from maternal blood through a test that could be widely available as early as 2012.

The KellBenx process involves the enrichment of these Fetal Nucleated Red Blood Cells (FNRBCs) with the antibodies licensed from AdnaGen to perform chromosomal or genetic analysis to identify markers of potential disorders.

KellBenx CEO Hassan Bennani said this agreement creates the opportunity to begin clinical testing of the exciting laboratory results they have produced over the past year, and it brings them one step closer to bringing a non-invasive prenatal blood test to the market that can detect genetic disorders.